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Platelets are blood cells with numerous crucial pathophysiological roles in hemostasis, cardiovascular
thrombotic events and cancer metastasis. Platelet activation requires the engagement of intracellular
signalling pathways that involve protein–protein interactions (PPIs). A better understanding of these
pathways is therefore crucial for the development of selective anti-platelet drugs. New strategies for
studying PPIs in human platelets are required to overcome limitations associated with conventional
platelet research methods. For example, small molecule inhibitors can lack selectivity and are often
diﬃcult to design and synthesise. Additionally, development of transgenic animal models is costly and
time-consuming and conventional recombinant techniques are ineﬀective due to the lack of a nucleus
in platelets. Herein, we describe the generation of a library of novel, functionalised stapled peptides and
their ﬁrst application in the investigation of platelet PPIs. Moreover, the use of platelet-permeable stapled
Bim BH3 peptides conﬁrms the part of Bim in phosphatidyl-serine (PS) exposure and reveals a role for
the Bim protein in platelet activatory processes. Our work demonstrates that functionalised stapled
peptides are a complementary alternative to conventional platelet research methods, and could make
a signiﬁcant contribution to the understanding of platelet signalling pathways and hence to the
development of anti-platelet drugs.Introduction
Platelets are blood cells that are maintained in the circulation in
an inactive state, but initiate thrombus formation upon acti-
vation. Signalling processes during platelet activation consist of
complex and nely regulated protein–protein interaction (PPI)
networks which have been the subject of considerable research
in recent years.1,2 The understanding of PPIs in platelets may
assist in the discovery of selective and specic anti-platelet
therapeutics which nd application in the treatment ofbridge, CB2 1EW, UK. E-mail: spring@ch.
ences, Anglia Ruskin University, CB1 1PT,
aZeneca, Cambridge, UK
, Technology and Research (A*STAR), 30
pore
ey, NSW 2006, Australia
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hnological University, 60 Nanyang Drive,
Cambridge, UK
tion (ESI) available. See DOI:
Chemistry 2018cardiovascular diseases and cancer therapy. However, current
methodologies used to investigate PPIs in human platelets have
several limitations. As platelets are anuclear, conventional
recombinant techniques to study the roles of proteins in
platelets are ineﬀective. Other experimental approaches include
the use of small molecule inhibitors and the generation and use
of transgenic animals.3 The use of small molecules is disad-
vantaged by the potential for oﬀ-target eﬀects, derived from the
lack of specicity among related targets.4 Moreover, the design
and development of small molecules targeting a shallow
protein–protein interface can be remarkably challenging
despite some recent advances.5 Conversely, generating trans-
genic animal models is time-consuming and costly, may be
prone to side-eﬀects during embryonic development, and may
not accurately represent the human situation.6 It is clear that
there is a need for new, complementary approaches that can be
used in human platelets directly, are easily designed, relatively
cheap, and selective.
Peptide-based therapeutics oﬀer a viable solution since they
are known to be potent and selective against biological targets
that are otherwise diﬃcult tomanipulate with small molecules.4
Such approaches have been used to manipulate intracellular
PPIs, wherein large and shallow contact areas of a protein are
successfully targeted by peptides, which are able to mimic theChem. Sci.
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View Article Onlinenative counter protein.4,7–10 Although highly potent and selec-
tive, peptides oen suﬀer from poor cell permeability, plasma
stability and hence poor bioavailability. To overcome the poor
pharmacokinetic properties of linear peptides, stapled peptides
have been successfully developed and used to target intracel-
lular PPIs.11–15 Indeed, an all-hydrocarbon stapled peptide,
ALRN-6924, is under clinical development as an anti-cancer
drug targeting HDM2/p53.16 Among the techniques used for
peptide stapling,17 the two-component double Cu-catalysed
azide–alkyne cycloaddition (CuAAC) strategy constrains the
peptides in the bioactive conformation and simultaneously
improves pharmacokinetic properties. Moreover, this strategy
uses unnatural azido amino acids that can be easily synthesised18
and facilitates the functionalisation of the staple with cell-
permeabilising motifs, uorescent-labelled tags and photo-
switchable linkers.19 The independent functionalisation of the
staple can be particularly useful when dealing with long and
synthetically challenging peptide sequences, as the complex
functionality is added to the staple rather than the N- or C-
terminus of the peptide. In addition, this approach only
requires one linear peptide to generate a variety of functionalised
stapled peptides, facilitating the exploration of various func-
tionalities on the linker and thus properties of the overall peptide.
Of particular interest in platelets is the investigation of PPIs
of the BCL-2 family members, in particular the BH3-only protein
family which has a key role in regulating intrinsic apoptosis and
the lifetime of platelets.20–23 Whilst all-hydrocarbon stapled
peptides corresponding to the BH3 domains of the BH3-only
protein family members have previously been used to investi-
gate apoptotic processes in haematological cancer cells, the
eﬃcacy of these molecules for use in platelets has yet to be
investigated. The BH3-only family of proteins has been exten-
sively studied and is therefore an ideal system to use to validate
our stapled peptide technology in human platelets.
Herein, we describe the rst application of stapled peptides
in human platelets. We investigate the potential of functional-
ised stapled peptides to enter the platelet cytosol and disrupt
biologically important intracellular processes involving BCL-2
proteins. We present a range of functionalised staples that
promote peptide uptake and reveal a new role for Bim BH3 inFig. 1 First application of functionalised stapled peptides in the
investigation of signalling pathways in human platelets. Peptide (red)
uptake is driven by the functionalised staple (orange). Once in the
cytosol the peptide is able to exert its biological activity by disrupting
platelet PPIs.
Chem. Sci.platelet activation (Fig. 1 and discussed later). Our work aims to
provide a complementary alternative to small molecule inhibi-
tors and transgenic animal models in the investigation of
intracellular signalling pathways in human platelets.
Furthermore, our research aims to act as the basis for the
future development of anti-platelet peptide-therapeutics that
have improved selectivity, enhanced stability, are easy to design,
synthesise and functionalise and most importantly can be
applied to human platelets directly.
Results and discussion
Platelet uptake of the model peptides
To investigate the potential of functionalised staples to modu-
late the uptake of stapled peptides into platelets, we used
a panel of een TAMRA-labelled model peptides stapled with
functionalised peptidic and non-peptidic groups (Fig. 2). The
model peptides used are based on the p53 sequence (a nuclear
eﬀector) and should therefore have no eﬀect on anucleated
platelets. Functionalisation of the peptides was easily achieved
using two-component CuAAC stapling technique, which
allowed incorporation of functionalised groups into the dia-
lkynyl linker, rather than to the N- or C-terminus of the peptide
sequence.24 This approach makes functionalisation of the
peptides easier since it requires the synthesis of one linear
peptide, with the functionality being provided by the staple.
Functionalised groups included: polycationic peptidic chains,17
the nuclear localisation sequences PKKRKV (NLS) derived from
SV40 large T-antigen and a novel polyguanidine small molecule
carrier (SMoC).25–30 Additionally, a panel of novel anionic and
polar peptidic chains was also screened (Fig. 2).
Washed platelet suspensions were incubated with peptides
for varying periods of time and cellular uptake was quantied
using ow cytometry. Treatment with 13–15 (carrying NLS) or 16
(bearing the SMoC motif) showed the highest platelet-
associated uorescence aer a 3 hour incubation (96.1 
0.8%, 98.1  1.1%, 97.5  1.4% and 96.1  2.2% positive
platelets for peptides 13 to 16 respectively), indicating signi-
cant association of the platelets with the stapled peptide.
Peptide 2 (ethyl ester) and the poly-arginine stapled peptides 4
and 5 showed intermediate uptake aer 3 hours (88.8  5.6%,
73.0  13.3% and 87.0  7.3% respectively for 2, 4 and 5). Only
34.9  7.8% of platelets were uorescent following 8 (poly-
lysine) treatments aer 3 hours. Changes in uorescence were
not observed with other peptides (Fig. 3A).
In order to explore the rate of peptide uptake, changes in
platelet uorescence were monitored during the rst 5 minutes
(Fig. 3B) and aer 15, 30, 45 and 60minutes following treatment
with peptides (Fig. SI_1, ESI†). More than 50% of platelets
became uorescent during the rst 15 minutes of incubation
with peptides 13–16, with a further increase aer the rst
45 minutes. Some 40–50% of platelets were uorescent aer
15 minutes following treatment with peptides 2, 5 or 8. No
further increase was observed thereaer (Fig. SI_1, ESI†).
Continuous assessment of peptide uptake in the rst 5 minutes
of treatment demonstrated that peptides 5 and 16 caused
a rapid increase in platelet uorescence (Fig. 3B).This journal is © The Royal Society of Chemistry 2018
Fig. 2 TAMRA labelled functionalised stapled peptides used to analyse platelet uptake of peptides. Schematics of the diﬀerent peptidic (blue),
non-peptidic functionalised staples (green) and a novel SMoC staple (pink). * indicates unlabelled peptides (N-terminus capped as acetyl).
Fig. 3 A functionalised staple is required to induce peptide uptake into platelets. (A) Platelets were incubated with TAMRA labelled model
peptides (10 mM ﬁnal concentration) for 1 h (white), 2 h (grey) and 3 h incubation (black) and the percentage positive for TAMRA ﬂuorescence was
quantiﬁed using ﬂow cytometry. (B) Peptides showing high uptake within the ﬁrst hour were analysed during ﬁrst 5 min following treatment.
Changes in platelet-associated ﬂuorescence were recorded in real time using ﬂow cytometry. Unlabelled platelets were recorded for 30 s prior
to addition of the given peptide. (C) Platelets were incubated with 10 mM of TAMRA-model peptides for 1 h prior to imaging by confocal
microscopy.‡
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View Article OnlineConfocal imaging demonstrated that peptides 5 and 13
permeated into the platelet cytosol, whilst treatment with 2, 8 or
16 showed predominant localisation to the platelet membrane
(Fig. 3C). Peptide uptake experiments of the most permeable
model peptides 5, 13–16 were repeated in the presence of
platelet-rich plasma (PRP) to ensure realistic conditions (ESI,
Fig. SI_2a†). The results showed only a small reduction in
peptide uptake between 10 and 20% indicating that the uptake
is not prevented by interaction with the other components of
the plasma.
Conventional platelet activation responses were assessed to
investigate potential oﬀ-target eﬀects of the peptide treatment.
Pleasingly, only low activation changes were observed followingThis journal is © The Royal Society of Chemistry 2018treatment with NLS-bearing peptides 13–15 and SMoC peptide
16 (Fig. SI_3, ESI†). No change in platelet activation markers
was observed for the other peptides, indicating that the treat-
ment of platelets with the model peptides did not result in non-
specic responses. Signicantly, undesired platelet aggregation
was only observed in response to treatment with peptide 16, but
not for the other peptides (Fig. SI_4, ESI†). Thus, peptide 16 was
excluded from further studies.
This data set provides evidence that functionalisation of
stapled peptides is required for the uptake of peptides into
platelets, with the NLS sequence (13–15) and poly-arginine
staple (5) being the most eﬀective. Further experiments were
performed to investigate whether stapled peptides based onChem. Sci.
Chemical Science Edge Article
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View Article Onlinea biologically relevant sequence were able to elicit a relevant
intracellular response in platelets.Eﬀect of Bim BH3 peptides on platelet PS exposure and
activation
Further experiments using peptides based around the Bim BH3
sequence were performed to determine whether platelet-
permeable peptides retained bio-functionality. The role of
BH3-only proteins in the development of a pro-coagulant
platelet phenotype has been investigated using the Bad BH3
mimetic small molecule ABT737. This induces mitochondrial
membrane depolarization, activation of caspases 9, 8
and3, phosphatidyl serine (PS) exposure and inhibition of the
platelet activation process by interacting indirectly with the pro-
apoptotic protein Bax via inhibition of the pro-survival BCL-2
proteins.31–34 Previous work has demonstrated that a Bim
sequence-based peptide (denoted Bim SAHBa) is able to induce
Bax mediated apoptotic responses in nucleated cells.35–37 To the
best of our knowledge, the implication of the interaction of Bim
BH3 with antiapoptotic and proapoptotic Bcl-2 proteins in
platelets is unknown, hence our interest in this PPI.
In order to demonstrate the eﬃcacy of functionalised group-
mediated peptide delivery in platelets, we synthesised two-
component stapled peptides based on the SAHBa sequence
and investigated the eﬀects of these on platelet processes.
Azido ornithine was employed as the unnatural amino acid
to perform the two-component double CuAAC stapling. This
facilitated the synthesis of diﬀerent stapled peptides from one
linear precursor: peptide 18with a non-functionalised staple, 19
with a poly-arginine staple and 20 with a NLS motif (Fig. 4).
Peptides 19 and 20 contain the same functionalised staples as
the model peptides with the highest cytosolic platelet uptake.
The inuence of these peptides on activatory processes in
washed platelet suspensions was compared with ABT737, which
causes PS exposure but does not activate platelets.31,33,38 Treat-
ment of platelets with 19 or 20, resulted in PS exposure (with 78Fig. 4 Bim BH3 stapled peptides. Peptide 17: wild-type Bim BH3
sequence. Amino acids that have been replaced with azido amino
acids to perform the CuAAC reactions are highlighted in red. * based
on the R153D mutant with sequence Ac-I-W-I-A-Q-E-L-D-Orn(N3)-
I-G-D-Orn(N3)-F-N-A-Y-Y-A-R-R-NH2.
Chem. Sci. 1.3% and 42.9  6.0% annexin V binding respectively aer 3
hours, Fig. 5A), consistent with the generation of a pro-
coagulant phenotype. Of note, 19 showed a similar prole to
ABT737, the previously reported clinical candidate and
appeared to be more potent than the all-hydrocarbon Bim
peptide (Fig. 5A). No annexin-V binding was observed following
treatment with the unstapled wild-type peptide 17 nor with the
non-functionalised stapled peptide 18. This can be explained by
the poor membrane permeability of peptides 17 and 18 and is
consistent with the behaviour of the non-functionalised model
peptide 1 (Fig. 2, ESI Fig. SI_2b, SI_5†). Even though FITC-
labelled peptide 18 showed high platelet uorescence in
plasma, confocal imaging showed the peptide forming aggre-
gates outside the platelet cytosol and hence being unable to
reach the target protein (ESI, Fig. SI_5†). Conversely, peptides
19 and 20 localized into the platelet cytosol with peptide 19
being the most eﬀective (ESI, Fig. SI_5†). Mutation of arginine
153 to aspartic acid (R153D) in the Bim BH3 domain (IWIA-
QELDRIGDEFNAYYARR) is unable to cause PS exposure in
nucleated cells.35 Therefore, we tested a R153D Bim stapled
peptide functionalised with poly-R3 (21). This peptide did not
result in PS exposure in platelets despite being platelet-
permeable (Fig. 5A, ESI Fig. SI_2b, SI_5†), suggesting that the
eﬀects of the BH3 stapled peptide are specic to biologically
relevant processes, and not due to non-specic, oﬀ target eﬀects.
Circular dichroism experiments showed the biologically
active stapled peptides to be helical, however there was no
enhancement in helicity for the stapled peptide compared to
the wild-type (Fig. SI_6, ESI†). Consistent with previous
reports,39 peptides retained biological activity despite the lack of
enhanced helicity in solution. Moreover, our results conrm
that a permeability-enhancing staple is required for the
peptides to reach the platelet cytosol, to eﬀect bioactivity and to
enhance stability in human serum (Fig. SI_7, ESI†). To investi-
gate whether the stapling aﬀects the ability of the peptides to
bind to their target proteins, we ran molecular dynamics (MD)
of an unfunctionalised form of peptides 19 and 20 in complex
with an antiapoptotic BCL-2 protein which is known to be
expressed in platelets, Bcl-xL.20 The simulations suggested that
the stapled peptide retains an a-helical conformation upon
binding and that its binding aﬃnity is comparable to that of the
unstapled wild-type peptide 17 (ESI Table SI_3, Fig. SI_10,
SI_11, ESI†). Encouraged by these results, we measured the
binding interaction of the wild-type and the stapled peptides in
a SPR assay. The results conrm that the wild-type and platelet-
permeable stapled peptide 19 are able to engage with Bcl-xL
protein (relative KDapp 7.3 and 26 nM respectively, ESI, Table
S1, Fig. SI_9†). Interestingly, the all-hydrocarbon Bim BH3
stapled peptide SAHBa showed a reduced binding aﬃnity
compared to the wild-type and peptide 19.
As previous work has indicated that the small molecule
ABT737 inhibits platelet activation, the eﬀect of stapled
peptides 19 and 20 on platelet activation markers was
assessed.40–42 Both peptides induced integrin aIIbb3 activation
(as measured by PAC-1 binding, Fig. 5B), whilst ABT737 was
ineﬀective. Peptide 19 or 20 treatment resulted in 24.1  2.4%
and 50.8  0.3% PAC1-positive platelets, respectively aer 1This journal is © The Royal Society of Chemistry 2018
Fig. 5 (A) Functionalised, stapled Bim BH3 peptides induce PS exposure in platelets. Platelets were treated with peptides and changes in
annexin-V binding were quantiﬁed using ﬂow cytometry. peptide 19, peptide 20 peptide 18, peptide 17, ABT737, peptide 12, vehicle
(DMSO), peptide 21, Bim SAHBa. (B) Stapled Bim BH3 peptides, but not ABT737 nor 21, induce platelet activation. Platelet activationmarkers (%
positive platelets) were investigated following 1 h of peptide treatment. PAC-1, CD62P and CD63 binding. Statistical signiﬁcance compared
to 20: ****P < 0.0001, ***P between 0.0001 and 0.0005, **P between 0.0010 and 0.0050 ns ¼ non-signiﬁcant.
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View Article Onlinehour. Treatment with either peptides resulted in similar levels
of CD62P expression (53.7  2.5% and 62.1  7.8%, for 19 and
20 respectively), indicating peptide-induced a granule secretion.
Additionally, both peptides increased CD63 expression (corre-
lated with dense granule release), with peptide 19 being more
eﬀective (72.9  5.3% compared to 34.4  6.7% for peptide 20).
Pleasingly, nonspecic activation was not observed when the
mutant R15D (21) was used. Despite having similar eﬀects on PS
exposure, no increase in any activation marker was observed
following treatment with ABT737. Whilst all the mimetics are
able to induce PS exposure, only the peptides induce upregula-
tion of platelet activation markers. Therefore, this data high-
lights that the mechanistic diﬀerences between the Bad BH3
mimetic ABT737 and the Bim BH3 mimetic stapled peptides 19
and 20 have diﬀerent eﬀects on platelet activatory responses and
therefore might nd diﬀerent therapeutic applications.Conclusions
This work is the rst to describe the use of functionalised
stapled peptides to perturb and investigate signalling pathways
in human platelets. We demonstrate the benets of using the
two-component CuAAC stapling technique to access a variety of
novel functionalised peptides from a synthesised linear
sequence. The nature of the motif (which is easily incorporated
onto the staple) impacts the ability of the peptides to enter the
platelet cytosol and modulate activity. This technique is
particularly powerful when long and complex sequences are
synthesised by solid-phase peptide synthesis as the cell-
permeable motif can be added onto the staple and therefore,
does not require the introduction of further complexity on the
linear sequence. We synthesised Bim BH3 mimetic peptides to
investigate PS exposure in platelets. The bioactivity of 19 was
comparable to that of the small molecule Bad mimetic ABT737.
Importantly, unlike ABT737, stapled peptides 19 and 20
(both Bim mimetics) caused platelet activation, demonstrating
diﬀerential activation of signalling pathways. Further studies
are currently underway in our labs to elucidate theseThis journal is © The Royal Society of Chemistry 2018mechanistic diﬀerences. Perturbation of the BCL-2 pathway
demonstrates the considerable potential of this technology to
investigate other PPIs in human platelets and for future devel-
opment of new anti-platelet drugs. One of the advantages of this
technology over small molecule use is the ease of design and
synthesis of the peptides, as they are a mimetic of the natural
components. Moreover, limitations such as the lack of
membrane permeability and poor serum stability are overcome
by the presence of the staple. The double click approach only
requires one linear peptide to enable the generation of a variety
of functionalised stapled peptides, which facilitates the explo-
ration of various functionalities on the linker and thus the
properties of the overall peptide. In addition, the easy func-
tionalisation of the staple provides the opportunity to incor-
porate a variety of motifs that could be useful for biological
testing (for example, uorophores, biotin and sequences regu-
lating controlled release) or for achieving selectivity. Most
importantly, this methodology allows testing in human plate-
lets directly, avoiding the inter-species diﬀerence, cost and time
limitations of transgenic animal models.
In theory, it is feasible that any PPI could be disrupted and
studied using functionalised peptides. Thus, the number of
potential targets that are accessible to study are increased. In
addition, considering the specicity and versatility of stapled
peptides, and the importance of platelets in many pathological
diseases,43,44 this work sets the basis for the future development
of specic anti-platelet peptide therapeutics.Conﬂicts of interest
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